Funding to Accelerate Life Science Research Reagents and In Vitro Diagnostics Raw Materials Production and Development WOBURN, Mass., February 22, 2021-- ABclonal Biotechnology, a global life science tools and services provider, recently completed its $92.9 million Series C financing led by Sequoia Capital China and healthcare-focused investor LYFE Capital. Other new and existing shareholders, such as Sigma Square Capital, Kinghall Ventures, and Lucion Capital, participated in the new round.